Blair William & Co. IL Purchases 33,725 Shares of Accolade, Inc. (NASDAQ:ACCD)

Blair William & Co. IL grew its position in shares of Accolade, Inc. (NASDAQ:ACCD) by 73.1% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 79,834 shares of the company’s stock after buying an additional 33,725 shares during the quarter. Blair William & Co. IL owned 0.10% of Accolade worth $286,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently modified their holdings of the company. Bellevue Group AG raised its holdings in shares of Accolade by 6.6% in the 1st quarter. Bellevue Group AG now owns 4,804,514 shares of the company’s stock worth $50,351,000 after purchasing an additional 297,110 shares during the period. Acadian Asset Management LLC bought a new stake in shares of Accolade in the 2nd quarter worth approximately $1,229,000. GSA Capital Partners LLP raised its holdings in shares of Accolade by 102.8% in the 1st quarter. GSA Capital Partners LLP now owns 51,374 shares of the company’s stock worth $538,000 after purchasing an additional 26,044 shares during the period. Allspring Global Investments Holdings LLC bought a new stake in shares of Accolade in the 1st quarter worth approximately $87,000. Finally, Charles Schwab Investment Management Inc. raised its holdings in shares of Accolade by 6.6% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 555,982 shares of the company’s stock worth $6,677,000 after purchasing an additional 34,559 shares during the period. Institutional investors own 84.99% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on ACCD. Truist Financial reduced their price objective on shares of Accolade from $14.00 to $9.00 and set a “buy” rating for the company in a research note on Friday, June 28th. Stifel Nicolaus reduced their price objective on shares of Accolade from $13.00 to $8.00 and set a “buy” rating for the company in a research note on Friday, June 28th. Morgan Stanley reduced their price objective on shares of Accolade from $12.00 to $6.00 and set an “equal weight” rating for the company in a research note on Friday, June 28th. Guggenheim reduced their price objective on shares of Accolade from $13.00 to $6.00 and set a “buy” rating for the company in a research note on Friday, June 28th. Finally, Canaccord Genuity Group reduced their price objective on shares of Accolade from $16.00 to $13.00 and set a “buy” rating for the company in a research note on Friday, June 28th. Three research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $11.65.

Accolade Price Performance

Shares of NASDAQ:ACCD opened at $3.86 on Friday. Accolade, Inc. has a 52-week low of $3.35 and a 52-week high of $15.36. The firm has a fifty day moving average of $4.02 and a 200 day moving average of $6.17. The firm has a market capitalization of $308.84 million, a PE ratio of -3.41 and a beta of 2.00. The company has a debt-to-equity ratio of 0.48, a quick ratio of 2.80 and a current ratio of 2.80.

Accolade (NASDAQ:ACCD) last announced its earnings results on Thursday, June 27th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.48) by $0.13. Accolade had a negative net margin of 20.62% and a negative return on equity of 20.30%. The company had revenue of $110.50 million during the quarter, compared to analyst estimates of $105.22 million. During the same period in the previous year, the business earned ($0.52) earnings per share. The firm’s quarterly revenue was up 18.6% compared to the same quarter last year. As a group, research analysts anticipate that Accolade, Inc. will post -1.11 EPS for the current fiscal year.

Accolade Profile

Accolade, Inc, together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based technology and multimodal support from a team of health assistants and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women's health specialists, case management specialists, expert medical opinion providers, and virtual primary care physicians.